Drug class
Somatostatin analogue ligand; precursor component for radiolabelled neuroendocrine-tumour imaging
Mechanism of action
A hydrazinonicotinyl-conjugated Tyr3-octreotide peptide that binds somatostatin receptors, particularly subtype 2, expressed by many neuroendocrine tumours. When radiolabelled with an appropriate radionuclide, the ligand enables scintigraphic or SPECT visualisation of receptor-positive lesions.
General use cases
- Investigational or specialised use as a peptide precursor in radiolabelled somatostatin-receptor imaging of neuroendocrine tumours; the final radionuclide-labelled product, not the unlabelled trifluoroacetate salt, is the diagnostic agent.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
